| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/28/2006 | US20060217289 Administering a polypeptide having an oxime-containing non-natural amino acid, from a translation system of: a polynucleotide comprising a selector codon encoding the polypeptide, a tRNA comprising the oxime-containing amino acid |
| 09/28/2006 | US20060216823 Method for obtaining an enriched population of siRNA-expressing cells |
| 09/28/2006 | US20060216820 Use of retinoic esters of hyaluronic acid for the differentiation of totipotent stem cells |
| 09/28/2006 | US20060216808 Isolated, recombinantly produced, enzymatically active hyaluronan synthase; a single protein that is a dual-action catalyst that utilizes UDP-GlcA and UDP-GlcNAc to synthesize hyaluronic acid |
| 09/28/2006 | US20060216799 Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide |
| 09/28/2006 | US20060216794 Hyaluronan synthase gene and uses thereof |
| 09/28/2006 | US20060216793 Culturing Bacillus strain with purified nucleic acid segment having coding region encoding enzymatically active hyaluronan synthase to produce hyaluronic acid; genetic engineering |
| 09/28/2006 | US20060216788 CASH (CASPASE HOMOLOGUE) with death effector domain, modulators of the function of FAS |
| 09/28/2006 | US20060216776 Screening assay for agents that alter target of rapamycin activity |
| 09/28/2006 | US20060216758 Antibodies to transferrin receptor-like proteins |
| 09/28/2006 | US20060216749 Chimeric gaba receptor |
| 09/28/2006 | US20060216747 first nucleotide sequence complementary to a target RNA sequence or a portion thereof, and a second sequence chemically modified so that it can no longer act as a guide sequence for mediating RNA interference, having complementarity to said first sequence; pharmaceutical use such as viricide |
| 09/28/2006 | US20060216745 Polynucleotides, expression vectors, and host cells for culturing truncated tryptophanyl-tRNA synthetase polypeptides having chemokine activity; bioassay; drug screening; antitumor agents, antimetastasis agents |
| 09/28/2006 | US20060216732 drug screening; identifying a therapeutic for decreasing intraocular pressure raised due to frizzled related protein (FRP) overexpression; contacting a trabecular meshwork cell expressing a Wnt pathway component or a frizzled related protein gene product with a test compound |
| 09/28/2006 | US20060216361 Compositions and methods for the treatment of osteoporosis and inflammatory joint disease |
| 09/28/2006 | US20060216360 Stable pharmaceutical compositions of platinum (II) antitumour agents |
| 09/28/2006 | US20060216359 Topical preparation for treating ulcerations on the inside of the month |
| 09/28/2006 | US20060216358 Such as strontium ranelate; once daily oral administration; various bone and glandular disorders |
| 09/28/2006 | US20060216353 Nanoparticulate corticosteroid and antihistamine formulations |
| 09/28/2006 | US20060216352 Rapid-acting pharmaceutical composition |
| 09/28/2006 | US20060216351 Pharmaceutical Compositions of Dispersions of Drugs and Neutral Polymers |
| 09/28/2006 | US20060216350 Ganglionic blocking agents for the treatment of epithelial diseases |
| 09/28/2006 | US20060216349 Ibuprofen composition |
| 09/28/2006 | US20060216348 Agglomerated starch compositions |
| 09/28/2006 | US20060216346 Dosage form containing (s)-pantoprazole as active ingredient |
| 09/28/2006 | US20060216345 Oral pharmaceutical composition including paroxetine |
| 09/28/2006 | US20060216344 Pharmaceutical compositions and dosage forms of thalidomide |
| 09/28/2006 | US20060216342 Micelle delivery system loaded with a pharmaceutical agent |
| 09/28/2006 | US20060216340 drug delivery at least two-day additional dosing interval; allows for reduced plasma concentrations over a prolonged time period while still providing effective pain management; transdermal delivery system maximizes the dosage interval |
| 09/28/2006 | US20060216338 Composition and method of treatment for heel pain |
| 09/28/2006 | US20060216336 Transdermal therapeutic system for Parkinson's Disease |
| 09/28/2006 | US20060216333 Methods related to the treatment of mucosal associated conditions |
| 09/28/2006 | US20060216328 Topical composition comprising a cyclofructan, a carrier and a drug |
| 09/28/2006 | US20060216323 Allograft composite of a biodegradable polyurethane based on a polyisocyanate and an optionally hydroxylated biomolecule to form a matrix for embedded reinforcement of bone and/or bone substitutes; resorbable polymers having osteopromotive/osteopermissive properties; no undesirable immune response |
| 09/28/2006 | US20060216317 Delivery of polynucleotide agents to the central nervous system |
| 09/28/2006 | US20060216316 Natural Killer T (NKT) cells; modulating immune responses, such as anti-cancer responses, and enhancing memory responses |
| 09/28/2006 | US20060216309 Identification of genes |
| 09/28/2006 | US20060216297 Method and composition for reducing blood sugar levels or fat storage by targeting cathepsin |
| 09/28/2006 | US20060216296 Compositions and methods for promoting or inhibiting angiogenesis |
| 09/28/2006 | US20060216295 Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy |
| 09/28/2006 | US20060216288 An anti-EGFR antibody such as Erbitux or panitumumab in combination with a VEGFR inhibitor such as vatalanib, sunitinib, erlotinib, or motesanib |
| 09/28/2006 | US20060216269 Dendritic cell tumor injection (DCTI) therapy |
| 09/28/2006 | US20060216268 Denaturants for sympathomimetic amine salts |
| 09/28/2006 | US20060216267 Topically applying an inexpensive, non-prescription, safe, polymerizable, hydrophobic, elastomeric solution of a polyether diamine, a secondary aromatic diamine, a polyisocyanate and a polyol to form a urea-linked polyetherurethane copolymer upon drying |
| 09/28/2006 | US20060216266 Alkyl ester alpha -cyanoacrylate monomers; saleable package containing the monomer and a polymerization initiator or accelerator and a therapeutical agent; internal adhesive that polymerizes in vivo, where the monomer and the resultant polymer are biocompatible and biodegradable |
| 09/28/2006 | US20060216265 Dendrimers as molecular translocators |
| 09/28/2006 | US20060216261 Nanoemulsion comprising metabolites of ginseng saponin as an active component and a method for preparing the same, and a skin-care composition for anti-aging containing the same |
| 09/28/2006 | US20060216258 Water-in-silicone emulsion compositions |
| 09/28/2006 | US20060216251 Topical formulations and methods of use |
| 09/28/2006 | US20060216249 Use of a cosmetic of pharmaceutical composition, comprising a lupeol-rich extract as an active ingredient for stimulating the synthesis of heat shock proteins |
| 09/28/2006 | US20060216245 Composition for local anesthesia |
| 09/28/2006 | US20060216244 Delivery of compounds for the treatment of parkinson's through an inhalation route |
| 09/28/2006 | US20060216243 Delivery of Beta-Blockers Through An Inhalation Route |
| 09/28/2006 | US20060216241 Transmucosal absorption through oral mucosa to systemic circulatory system; bioavailability, rapid onset; active ingredient, solvent and low molecular weight hydrocarbon propellant; anxiety, muscle spasms |
| 09/28/2006 | US20060216240 Transmucosal absorption through oral mucosa to systemic circulatory system; bioavailability, rapid onset; active ingredient, solvent and low molecular weight hydrocarbon propellant; sleep disorders |
| 09/28/2006 | US20060214141 Luminescent illumination adjunct for night vision |
| 09/28/2006 | US20060214037 Wet milling process |
| 09/28/2006 | US20060213156 Animal cover having a temperature altering device |
| 09/28/2006 | DE202005020539U1 Aripiprazol Aripiprazole |
| 09/28/2006 | DE102006012107A1 Verwendung von Estern der Angelicasäure als antiphlogistischen Wirkstoff, sowie antiphlogistische Zubereitungen The use of esters of angelic acid as anti-inflammatory active substance, as well as anti-inflammatory preparations |
| 09/28/2006 | DE102005027150A1 Pyrimidincarbonsäure-Derivate und ihre Verwendung Pyrimidinecarboxylic acid derivatives and their use |
| 09/28/2006 | DE102005014628A1 New substituted oxindole derivatives are vasopressin receptor binders useful to treat e.g. diabetes insipidus, enuresis nocturna, incontinence, hypertonia, heart failure, myocardial infarction, coronary spasm and renal disorders |
| 09/28/2006 | DE102005014141A1 Tablettenförmige Retardzubereitung gegen Schwindel Delayed-release tablets shaped against scams |
| 09/28/2006 | DE102005014090A1 5H-Benzocycloheptenderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer 5H-Benzocycloheptenderivate, processes for their preparation and their use as anti-inflammatories |
| 09/28/2006 | DE102005014089A1 Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer Tetrahydronaphthalene derivatives, processes for their preparation and their use as anti-inflammatories |
| 09/28/2006 | DE102005014080A1 Additionssalze des Tolperison, Verfahren zu deren Herstellung und Verwendung derselben Addition salts of tolperisone, processes for their preparation and use thereof |
| 09/28/2006 | DE102005013622A1 New tricyclic thiophene or furan derivatives useful as tumor necrosis factor alpha inhibitors, e.g. for treating asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, osteoarthritis, multiple sclerosis |
| 09/28/2006 | DE102005013621A1 Substituierte 2-Aryl(Hetaryl)-5-aminothieno[2,3-d]pyrimidin-6-carbonsäureamide, Verfahren zu ihrer Herstellung und Verwendung als Pharmazeutika Substituted 2-aryl (heteroaryl) -5-aminothieno [2,3-d] pyrimidin-6-carboxamides, process for their preparation and use as pharmaceuticals |
| 09/28/2006 | DE102005012971A1 Polymorphe Form von 6-(4-Chlorphenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl-essigsäure Polymorphic form of 6- (4-chlorophenyl) -2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl-acetic acid |
| 09/28/2006 | DE102005012873A1 Aminocarbonyl substituierte 8-N-Benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Aminocarbonyl substituted 8-N-benzimidazoles, process for their preparation and their use as medicaments |
| 09/28/2006 | DE102005012872A1 Substituierte, bizyklische 8-Pyrrolidino-benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Substituted bicyclic 8-pyrrolidino-benzimidazoles, process for their preparation and their use as medicaments |
| 09/28/2006 | DE102004039533B4 Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel Cyclohexylmethoxy-acetic acid derivatives having substituents, processes for their preparation and their use as medicaments |
| 09/28/2006 | CA2831416A1 The use of a prostaglandin for treating mucosal disorders |
| 09/28/2006 | CA2821645A1 A pharmaceutical composition for treating depression and method for preparation thereof |
| 09/28/2006 | CA2646729A1 Methods and compositions for the treatment of urinary incontinence |
| 09/28/2006 | CA2611137A1 Water-dispersible carotenoids, including analogs and derivatives |
| 09/28/2006 | CA2609615A1 Medicinal compositions of salts, chelates and/or free acids of alpha hydroxyl organic acids and related processes and methods |
| 09/28/2006 | CA2608071A1 Intravascular, interstitial or intraorgan medical access device, and manufacturing method thereof, involving nitric oxide |
| 09/28/2006 | CA2606247A1 Composition comprising n-propanoyl derivatives of amino acids, aminocarbohydrates and derivatives thereof |
| 09/28/2006 | CA2602698A1 Derivative compounds of 5?thioxylose and their uses for the treatment or prevention of thromboses or cardiac insufficiency |
| 09/28/2006 | CA2602583A1 Biaryl derived amide modulators of vanilloid vr1 receptor |
| 09/28/2006 | CA2602559A1 Agent for treatment of hematopoietic tumor |
| 09/28/2006 | CA2602545A1 Phenyl-n-acyl derivatives of amines and amino acids, a process for the preparation thereof, a pharmaceutical composition and the use thereof |
| 09/28/2006 | CA2602541A1 Isoflavonoid dimers |
| 09/28/2006 | CA2602534A1 Transdermal patch |
| 09/28/2006 | CA2602525A1 Drug delivery systems for treatment of diseases or conditions |
| 09/28/2006 | CA2602514A1 Use of substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines for the treatment of reperfusion injury and reperfusion damage |
| 09/28/2006 | CA2602484A1 Topical formulations of borinic acid antibodies and their methods of use |
| 09/28/2006 | CA2602478A1 Novel thiophene derivatives |
| 09/28/2006 | CA2602475A1 Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists |
| 09/28/2006 | CA2602474A1 Hydrogenated benzo (c) thiophene derivatives as immunomodulators |
| 09/28/2006 | CA2602445A1 Metabolites for nk-i antagonists for emesis |
| 09/28/2006 | CA2602444A1 Acetylenyl-pyrazolo-pyrimidine derivatives as mglur2 antagonists |
| 09/28/2006 | CA2602397A1 Therapeutic agent for solid tumor |
| 09/28/2006 | CA2602395A1 2,3-substituted fused pyrimidin-4(3h)-ones as vr1 antagonists |
| 09/28/2006 | CA2602392A1 Solubilized ibuprofen |
| 09/28/2006 | CA2602383A1 Substituted triazole derivatives as oxytocin antagonists |
| 09/28/2006 | CA2602374A1 Composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a cox-2 inhibitor |
| 09/28/2006 | CA2602358A1 4-piperazinnylthieno [2,3-d] pyrimidine compounds as platelet aggregation inhibitors |
| 09/28/2006 | CA2602341A1 Nanoparticulate corticosteroid and antihistamine formulations |